C ardiac resynchronization therapy (CRT) has been shown to reduce heart failure symptoms, hospitalizations, and mortality while improving quality of life in selected patients with heart failure with reduced ejection fraction and electrocardiographic evidence of ventricular dyssynchrony. 1-5 The benefits of CRT, however, are not uniform and depend on both QRS morphology and QRS duration. 6,7 Current professional society guidelines reserve the highest recommendation for CRT-defibrillator (CRT-D) implantation in patients with heart failure with reduced ejection fraction, a left bundle branch block (LBBB), and QRS ≥150 ms (class I recommendation). 8 The recommendations for those without LBBB are more equivocal (class IIa or IIb recommendation dependent on QRS duration). 8 In available analyses of clinical trials and observational data, women tend to do better with CRT-D than men. [9] [10] [11] Background-Women have been under-represented in trials of cardiac resynchronization therapy-defibrillators (CRT-D).
One possible explanation for this is that women more often have LBBB, which is associated with a better CRT response. However, electrophysiology and preclinical studies have shown that approximately one third of patients diagnosed with LBBB by conventional ECG criteria do not have endocardial activation consistent with a true LBBB, [12] [13] [14] confirming an inherent difficulty of diagnosing LBBB. Because women have smaller hearts and a shorter QRS duration at baseline compared with men, 15 they may also have a true LBBB at a shorter QRS duration than men. To account for these differences between women and men, stricter ECG LBBB criteria were proposed that require a QRS ≥130 ms in women and ≥140 ms in men, along with mid QRS notching or slurring. 13 A prior study of 3 randomized clinical CRT-D trials in primarily mild heart failure patients (New York Heart Association [NYHA] class II) showed that women with LBBB and QRS duration ≥130 ms had a mortality benefit from CRT-D while men with LBBB benefited at QRS ≥150 ms. 16 However, in a large real-world population of only CRT-D patients included in the National Cardiovascular Data Registry (NCDR) implantable cardioverter defibrillator (ICD) Registry (primarily NYHA class III), it was observed that both women and men had a lower mortality risk with LBBB and QRS ≥140 ms. 17 It is difficult to assess the real-world performance of CRT-D when only a narrowly selected patient population is available (clinical trials) or when a standard ICD group is not included. The objective of the current analysis was to compare longterm mortality outcomes between real-world CRT-D and ICD patients among subgroups by sex, bundle branch block, and QRS duration in the NCDR ICD Registry in NYHA class III or IV heart failure.
Methods
This study was approved by the US Food and Drug Administration Research in Human Subjects Committee and the Yale University Human Investigation Committee. It included all patients in the NCDR ICD registry who received a first time CRT-D or ICD implant between January 1, 2006, and March 31, 2010, had NYHA class III or IV heart failure symptoms, and had QRS duration between 120 and 220 ms (n=86 967). Demographics and covariates were collected using standardized data elements in the NCDR including all variables in the Table and additionally: syncope, family history of sudden death, cardiac arrest, ventricular tachycardia, previous myocardial infarction, previous cardiac procedures (including percutaneous coronary intervention and coronary artery bypass graft), and systolic blood pressure. Post discharge medications were also available. QRS morphology was defined by the criteria used in the NCDR. 18 The outcome for this analysis was time to all-cause mortality obtained by linking NCDR registry files with the Social Security Death Master File. The following patients were excluded from the analysis: patients with a missing ICD type (single chamber, dual chamber, or CRT-D; n=723), epicardial leads (n=9326), missing data for sex, QRS duration or bundle branch block type (n=61), and patients who were unable to be linked to the Social Security Death Master File or had a death date before implant date (n=1778). Only patients with NYHA class III or IV were included because patients with NYHA class I or II heart failure were not part of professional society guidelines and Food and Drug Administration indications for use of CRT-D between 2006 and 2010. In addition, the specific NYHA class was a strong predictor of CRT-D use within the total population of NYHA class I-IV heart failure patients, making it difficult to apply propensity score analysis to account for measured confounders and selection bias. Patients with QRS >220 ms were excluded because of the small number of subjects in this category.
Statistical Analysis
Patients were stratified by sex, bundle branch block type, and QRS duration in 10-ms increments. To account for potential treatment selection bias and to control for differences in case-mix between CRT-D and ICD, we used inverse probability treatment weighting based on the propensity score. Propensity scores were calculated using logistic regression incorporating all covariates and with receiving CRT-D (versus ICD) as the outcome resulting in the predicted probability of receiving CRT-D based on these covariates. Weighted propensity scores were then calculated by weighting each patient who received CRT-D by the inverse of the probability that the patient would be selected for CRT-D as well as by weighting each patient who received ICD by the inverse of the probability that the patient would be selected for ICD. To stabilize the weights, we used the marginal probability of receiving CRT-D as standard weights can be highly variable. 19 Weighted propensity score analysis was then repeated, reweighting all baseline characteristics in all subgroups. Standardized differences after weighting were calculated to ensure balanced treatment groups with respect to baseline characteristics. CRT-D and ICD groups were considered balanced when the standardized difference is <10% because this indicates insignificant differences in covariates between groups. 20 Time-to-all-cause mortality data are presented using propensity score weighted Kaplan-Meier survival curves for the total cohort and subgroups, and weighted Cox proportional hazards models were used to assess mortality risk between CRT-D and ICD, including weighted sex-by-treatment interactions. The proportional hazards assumption was assessed by including a time×device interaction and was found nonsignificant in all models. Missing data were rare for all variables (between 0.008% and 0.58%) and were imputed by the most common value for categorical variables and medians for continuous variables. 21 Separate analysis was conducted substratifying the non-LBBB group into right bundle branch block (RBBB) and
WHAT IS KNOWN
• Cardiac resynchronization therapy-defibrillators have been shown in clinical trials to reduce symptoms, hospitalization, and mortality while improving quality of life in selected patients with heart failure, systolic dysfunction, and abnormal intraventricular conduction. • Previous studies suggest that cardiac resynchronization therapy-defibrillators may provide more benefit in women than men and that there may be no benefit in patients without left bundle branch block regardless of sex.
WHAT THE STUDY ADDS
• In a large real-world cohort from the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry, cardiac resynchronization therapy-defibrillator was, when compared with implantable cardioverter defibrillator, associated with a lower mortality in both sexes with left bundle branch block, although more pronounced among women. The mortality differences in patients without left bundle branch block were attenuated in both sexes. • Only in patients with left bundle branch block did both sexes have lower mortality with longer QRS duration.
nonspecific intraventricular conduction delay (IVCD). All statistical analyses were conducted with SAS software, version 9.3 (SAS institute, Cary, NC). Ninety-five percent confidence intervals (CIs) are reported for all hazard ratios (HRs), and a prespecified P value <0.05 (not adjusted for multiplicity) was considered statistically significant.
Results
The total study cohort consisted of 75 079 patients of which 23 744 (32%) were women and 51 335 (68%) were men. Approximately 84% of patients received a CRT-D and 16% received ICD. The proportion of ICD recipients decreased . After subsequent inverse probability treatment weighting, the CRT-D and ICD groups in both sexes were balanced indicated by standardized differences <10% for all variables (Table) . This was also true for CRT-D and ICD groups in all other stratified analyses (Tables II and III in the Data Supplement). In the overall weighted cohorts, the main baseline differences between sexes included women (compared with men) having more LBBB (81% versus 61%), nonischemic cardiomyopathy (55% versus 30%), and normal atrioventricular conduction (79% versus 69%), while they had less atrial fibrillation/flutter (23% versus 34%; Table) . The majority had NYHA class III heart failure symptoms (93% of both women and men). The mean followup for the overall cohort was 2.5±1.3 years while the median follow-up was 2.5 years (interquartile range, 1.5-3.6 years). The overall mortality rate in the total weighted cohort of CRT-D and ICD patients was lower in women than in men (Figure 1) . After a mean follow-up time of 2.5 years, female patients with CRT-D had a lower mortality risk than those with an ICD (absolute CRT-D to ICD difference, 11%; HR=0.77; 95% CI, 0.72-0.82; P<0.001). Men with CRT-D also had a lower mortality compared with those with an ICD, but this was less pronounced than in women (absolute difference, 7%; HR=0.88; 95% CI, 0.85-0.92; P<0.001). This mortality difference between sexes was significant (P<0.001 for sex×device interaction).
Mortality in Patients With LBBB
Among patients with LBBB, a similar pattern as for the total cohort-a lower mortality in women compared with menwas observed; however, the overall lower mortality associated with CRT-D versus ICD was greater than in the total cohort ( Figure 2 ). Both women and men with LBBB had a lower mortality risk with CRT-D compared with ICD (absolute difference, 11%; HR=0.74; 95% CI, 0.68-0.81; P<0.001 for women and absolute difference, 9%; HR=0.84; 95% CI, 0.79-0.89; P<0.001 for men), but with a greater effect in women (P=0.025 for interaction). Although none of the patients with LBBB and QRS 120 to 129 ms had a lower mortality risk with CRT-D compared with ICD, both women and men with LBBB and a QRS ≥130 ms had a significantly lower mortality risk (Figure 3 ). Although this lower mortality rate persisted in women with longer QRS durations 150 to 170 ms, the upper confidence limit just crossed HR=1 for men. There were no significant device interactions by sex within any of the QRS duration groups (Figure 3 ).
Mortality in Patients Without LBBB
Women and men without LBBB had a slightly lower mortality rate with CRT-D compared with ICD (absolute difference, 3%; HR=0.88; 95% CI, 0.79-0.97; P=0.014 for women and absolute difference, 2%; HR=0.95; 95% CI, 0.91-0.998; P=0.042 for men; Figure 2 ). There was no statistical difference in the relationship between CRT-D and mortality between sexes (P=0.17 for interaction); women without LBBB did not seem to confer any additional mortality risk difference compared with men without LBBB. There was also no clear mortality risk difference with CRT-D in non-LBBB women or men within any of the 10 ms QRS duration groups, except for women with QRS 150 to 159 ms (Figure 3) .
Analysis dividing the non-LBBB cohort into patients with either RBBB (n=9209) or IVCD (n=10 212) was conducted. In RBBB, there was no lower mortality with CRT-D and no difference between women and men (absolute difference, 1%; HR=0.98; 95% CI, 0.83-1.16; P=0.82 in women and absolute difference, 1%; HR=0.97; 95% CI, 0.90-1.05; P=0.44 in men; P=0.90 for interaction). With IVCD, there was no lower mortality risk with CRT-D in men (absolute difference, 4%; HR=0.93; 95% CI, 0.86-1.01; P=0.076); however, women with IVCD had a slightly lower mortality risk with CRT-D (absolute difference, 7%; HR=0.76; 95% CI, 0.65-0.88; P<0.001; P=0.02 for sex×device interaction in IVCD; Figure 4 ).
Discussion
In this observational analysis of a large real-world cohort of patients with NYHA class III or IV heart failure and reduced ejection fraction, we found that, compared with ICD, CRT-D was associated with a greater difference in mortality in women than in men, but this lower mortality risk was more evident in both male and female patients with LBBB. Among all LBBB patients, both women and men generally had lower mortality risks with QRS ≥130 ms; however, the mortality difference associated with CRT-D was greater in women. In the non-LBBB cohort, there was no mortality risk difference between CRT-D and ICD in women or men with RBBB or in men with IVCD. The finding that there seems to be reduced mortality in patients with LBBB and QRS 130 to 150 ms is important because professional society guidelines for CRT only assign a class I recommendation to patients with LBBB and QRS ≥150 ms. 8 That CRT is effective in LBBB has been shown in recent meta-analyses of clinical trials, 7, 16, 22 whereas other studies have suggested that CRT is less effective or can even be harmful in patients without LBBB. 7, [23] [24] [25] [26] [27] [28] One third of patients diagnosed with LBBB by conventional criteria, however, do not Figure 3 . Propensity score-weighted mortality hazard ratios by sex for QRS duration groups in left bundle branch block (LBBB) and non-LBBB. Points reflect cardiac resynchronization therapy-defibrillator (CRT-D) to implantable cardioverter defibrillator (ICD) mortality hazard ratios in 10 ms QRS duration groups in women and men after propensity score weighting for LBBB (left) and non-LBBB (right). Lines reflect 95% confidence intervals, and sex×device interaction P values are reported for every QRS duration group. Vertical lines indicate no difference between CRT-D and ICD (hazard ratio=1). See Table IV in have endocardial activation consistent with a true LBBB, [12] [13] [14] supporting the challenges in diagnosing LBBB on the surface ECG. In addition, because women have smaller ventricles and a shorter QRS duration at baseline compared with men, 15 they may also have a true LBBB at a shorter QRS duration ≥120 ms than men. Recent stricter LBBB criteria accounting for this difference between women and men, requiring a QRS ≥130 ms in women and ≥140 ms in men along with mid-QRS notching or slurring, 13 have shown to be associated with lower risks of mortality and heart failure hospitalization with CRT. 29, 30 A previous individual-patient data meta-analysis of 3 large premarket clinical trials primarily enrolling NYHA class II heart failure patients found that women with LBBB benefited from CRT-D compared with ICD with QRS ≥130 ms while men with LBBB benefited with QRS ≥150 ms. 16 The present study showed that both women and men with CRT-D had a lower mortality risk with LBBB and QRS ≥130 ms compared with those with an ICD. However, patients in this study were not part of a selected clinical trial patient population and primarily had NYHA class III heart failure symptoms. In addition, men with LBBB and QRS 130 to 139 ms may have had a lower mortality risk with CRT-D because ICD patients with shorter QRS duration were sicker compared with CRT-D patients (discussed further below).
Other factors that may have contributed to a greater CRT effect in women compared with men are the higher rate of nonischemic cardiomyopathy and lower rate of atrial fibrillation/flutter, factors that have been associated with a better response to CRT. 31 Adjustment for these variables, however, still did not explain the differences between women and men. Interestingly, a previous study of only CRT-D recipients in the NCDR observed that both women and men with LBBB and QRS ≥140 ms had a lower mortality risk, 17 and a separate meta-analysis showed a beneficial CRT effect in patients with QRS ≥140 ms in which sex was not predictive, although neither was bundle branch block type. 22 The extended follow-up of the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) also showed that there was no difference between women and men with LBBB. 32 Separate studies that evaluated the effect of CRT by sex have shown slightly different results, 9, 22, 28 whereas other published analyses on CRT by bundle branch block type and QRS duration have not included sex-specific analysis. 6, 7, 23, 25, 33 In this analysis, we observed that patients without LBBB receiving CRT-D had a lower mortality risk than non-LBBB ICD patients, although the difference was small (absolute risk difference of 2% in men and 3% in women). A small beneficial effect of CRT has also been observed for certain patients without LBBB in previous studies and may be caused by multiple factors. 34, 35 A recent post hoc analysis of MADIT-CRT found that patients with non-LBBB who had extremely long PR intervals at baseline benefited from CRT. This suggests that optimizing atrioventricular delay may provide some benefit in these patients. 35 However, when we evaluated RBBB and IVCD patients in the non-LBBB cohort, we did not observe a lower mortality risk for women or men with RBBB and men with IVCD while there was a slightly lower mortality in women with IVCD. Of note, we did not observe a consistent lower mortality risk in the total non-LBBB cohort across QRS duration (Figure 3 ).
We observed that ICD patients with shorter QRS duration were sicker because they had more ventricular tachycardia, ischemic heart disease, and a higher rate of heart failure hospitalization in the previous 6 months compared with ICD patients with a longer QRS duration (data not shown). This may have contributed to men with LBBB and QRS 150 to 159 and 160 to 169 ms only trending toward a lower mortality risk with CRT-D and why LBBB men with a CRT-D and shorter QRS duration had lower mortality than LBBB men with CRT-D and longer QRS duration.
Limitations
This was an observational study in primarily NYHA class III heart failure patients, and we were not able to assess the relationship between CRT-D and survival outside of this patient population. In addition, this study was not able to comment on other clinical events such as hospitalization for heart failure or heart failure symptom status. Furthermore, multiple comparisons were performed, and P values were not adjusted for multiplicity potentially influencing statistical significance. However, with a conservative Bonferroni correction, P values would still be significant (P<0.001 for all comparisons in LBBB). Entry errors or missing data may have resulted in misdiagnosis of baseline characteristics including QRS morphology and QRS duration; however, prior analysis has shown that data accuracy for the NCDR ICD Registry is ≈91%. 36 Although important cardiac covariates (NYHA class, ejection fraction, bundle branch block type, and QRS duration) were included in the analysis and propensity score weighting was used to balance characteristics between CRT-D and ICD groups, there is the possibility of unmeasured patient characteristics influencing all-cause mortality because noncardiac competing factors for death were not included and propensity score weighting does not adjust for unobserved variables. Even though the proportion of ICD recipients was relatively low (≈16%) and decreased over time, there may have been temporal selection bias because some ICD patients in this study would receive CRT-D instead of ICD according to contemporary practice. Finally, unmeasured characteristics may have contributed to treatment selection bias in choosing CRT-D versus ICD.
Conclusions
In a large real-world population of CRT-D and ICD patients with primarily NYHA class III heart failure, CRT-D was associated with a significantly lower mortality risk in women than in men, and this lower mortality risk increased for both sexes with LBBB. In non-LBBB, there was a much smaller effect of CRT-D and no difference between sexes. Furthermore, only among LBBB patients, both women and men had lower mortality risks with QRS ≥130 ms, whereas QRS duration had no effect on mortality in non-LBBB patients. RBBB patients did not experience a mortality risk benefit regardless of sex. Potential unmeasured patient characteristics not adjusted for by propensity score weighting may have influenced the results.
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